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Abstract
Objectives. The role of inflammation in OA is controversial and it is unclear whether suppressing inflammation with
conventional or biologic DMARDs is effective. A systematic review and meta-analysis of randomized controlled trials
(RCTs) was conducted to compare DMARDs with placebo in participants with symptomatic OA.
Methods. Databases (Medline, Embase, Allied and Complementary Medicine Database, Web of Science and Cochrane
Library), conference abstracts and ClinicalTrials.gov were searched to end of November 2017 for placebo-controlled
RCTs of DMARDs, including biologics, in symptomatic OA. Pain data at treatment peak time point were extracted and
combined using a random-effects meta-analysis. Markers of inflammation and adverse events were extracted and re-
viewed. Risk of bias assessment was conducted using Cochrane’s tool.
Results. Eleven RCTs (1205 participants) were meta-analysed, including six for conventional DMARDs (757 participants)
and five for biologics (448 participants). Overall, DMARDs were statistically superior to placebo [effect size (ES) = 0.18,
95% CI: 0.03, 0.34], although the difference was not clinically significant (0.5 ES threshold). Furthermore, no statistically
significant differences were observed in sub-analysis of high-quality trials (ES = 0.11, 95% CI : 0.06, 0.28), biologics
(ES = 0.16, 95% CI: 0.02, 0.34) or conventional DMARDs (ES = 0.24, 95% CI: 0.05, 0.54). No difference was found
between erosive vs non-erosive hand OA, hand vs knee OA or anti-IL1 vs anti-TNF biologics.
Conclusion. DMARDs did not offer clinically significant pain relief above placebo in OA. This poor efficacy indicates
that inflammation may not be a prime driver for OA pain.
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Rheumatology key messages
. No clinically significant pain relief is offered by DMARDs (compared with placebo) in OA.
. No statistically significant difference was observed between various drugs, drug targets, joint sites, or OA
subtypes.
. Inflammation in OA may not be a major risk factor for OA pain.
Introduction
OA is a major cause of pain and disability for which no
disease-modifying drug interventions have yet been
identified. It is a common complex disorder that involves
all joint tissues and affects approximately 1 in 5 women
and 1 in 10 men aged >60 years [1]. The pathogenesis
of OA has not been fully characterized, and the role
of synovial inflammation within this process is intensely
debated.
Some perceive OA as the inherent repair process of
synovial joints in which modest inflammation is secondary
to joint tissue damage caused largely by biomechanical
insult [2]. In contrast, others believe synovial inflammation
to be a more primary feature and a central driver of OA
pain and progression [3]. This belief has encouraged the
conduct of randomized controlled trials (RCTs) of conven-
tional and biologic DMARDs in OA. These potent agents
are used in inflammatory arthritides, such as RA, where
they suppress the aggressive primary inflammation that
drives the disease [4].
Conventional and biologic DMARDs are the two major
classes of DMARDs used for RA. Conventional DMARDs
include drugs such as MTX and HCQ [4], whereas biologic
DMARDs are mAbs and soluble receptors that target pro-
tein messenger molecules or cells [4].
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Whether DMARDs are effective for OA remains contro-
versial. The literature is scattered with hypotheses and
hopes for a positive effect in OA. However, this is inter-
spersed with reports of treatment failures. We therefore
undertook the present meta-analysis to examine the effi-
cacy of DMARDs, including both conventional and bio-
logic DMARDs, in participants with symptomatic OA.
Methods
Placebo-controlled RCTs comparing a DMARD, including
biologics, with placebo in participants with symptomatic
OA at any site were included. DMARDs that are recom-
mended or licensed for RA were considered for this review
[5, 6]. Supplementary Table S1, available at Rheumatology
online, lists all drugs eligible for inclusion in the review. Full
text publications and conference abstracts in any language
were accepted. No limits were set for publication year.
A systematic literature search was conducted across five
databases: Medline, Embase, Allied and Complementary
Medicine Database, Web of Science and Cochrane
Library. The full search strategies are available in supple-
mentary Table S2, available at Rheumatology online. The
search was run from date of database inception to 30
November 2017. Additional trials were searched for using
the online clinical trial register ClinicalTrials.gov and
EULAR, OARSI and ACR annual meeting abstracts.
Following the removal of duplicates, all trials were exam-
ined for eligibility. Full texts of eligible abstracts were
sought and used. Where full texts were unavailable, con-
ference abstracts were included to minimize publication
bias and to ensure the evidence captured was current.
The data were extracted independently by two reviewers
(M.S.M.P. and A.S.) using a Microsoft Access extraction
form created for this review. The following information
was extracted: publication details, including author, journal,
year and publication type (full text or abstract); trial details,
including trial funder, study design, blinding and duration;
participant details and demographics, including number of
participants, age, gender distributions and BMI; the joint
affected; method of diagnosis (e.g. clinical, radiographic);
OA subset details; and intervention/control details, includ-
ing the drug, formulation, dose and frequency.
Pain data at treatment peak time point were extracted.
Treatment peak time point (i.e. time point where treatment
group had the greatest improvement) was chosen under
the assumption that if a difference between treatment and
placebo was not observed at this time point, one could
confidently assume no efficacy at other time points.
Where multiple tools for assessing pain were presented,
the outcome was chosen using the hierarchy defined by
Ju¨ni et al. [7]. Where possible, changes from baseline pain
scores were extracted/calculated; if not, end point scores
were used to calculate the between-group mean differ-
ences. If pain outcomes were dichotomized, the per-
centage of participants with improvement in pain (as
defined in the publication) was used. Data were preferen-
tially extracted from intention-to-treat analyses. Data were
not extracted from graphs, and missing data were not
sought from investigators. Where a trial examined multiple
dosages of the intervention, these were combined into
one group for analyses.
Other outcomes extracted were inflammation (local or
systemic) and incidence of adverse events (AEs).
Risk of bias
Two reviewers independently assessed the risk of bias of
included trials using Cochrane’s Risk of Bias Tool [8]. The
distribution of scores for each domain was presented.
Statistical methods
Hedges’ effect size (ES) and corresponding 95% CI were
calculated. If dichotomized, the odds ratio for improve-
ment was extracted/calculated and converted to an ES
[8, 9]. The study estimates were combined using a
random-effects meta-analysis weighted using inverse-
variance methods. Heterogeneity was quantified using
I2, and the P-value was calculated using the Q test [10,
11]. Publication bias was presented using a funnel plot,
and the asymmetry of this plot was examined by Egger’s
test [12]. As recommended in the National Institute for
Health and Care Excellence guidelines for OA, a minimal
clinically important difference threshold of ES = 0.5 for the
lower level of the 95% CI was used to determine clinical
significance [13].
All DMARDs were pooled before being examined by
type (conventional vs biologic). Further subgroup analysis
was conducted to examine biologics by the mechanism of
action (TNF-inhibitor vs IL1-inhibitor). Additional subgroup
analyses were conducted by joint affected, OA subtype
(erosive vs non-erosive hand OA) and publication type. A
sensitivity analysis was only conducted for high-quality
trials using adequate allocation concealment as an indi-
cator of quality [14].
Analyses were done with Stata (StataCorp. 2015. Stata
Statistical Software: Release 14. College Station, TX,
USA: StataCorp LP). The trial was registered with
PROSPERO (PROSPERO 2017 CRD42017067427).
Results
Description of trials
Thirteen studies were identified comparing a DMARD with
placebo in participants with OA (Fig. 1 and Table 1).
Outcome data were not available for extraction from two
abstracts [15, 16]. The meta-analysis is based on the re-
maining 11 RCTs (7 full texts, 4 abstracts), including 6 for
conventional [2527] and 5 for biologic [1820, 24, 23]
DMARDs. A variety of DMARDs were examined, including
HCQ (5 trials) [17, 21, 22, 26, 27], MTX (1 trial) [25], ana-
kinra (ANK; 1 trial) [19], adalimumab (ADA, 3 trials) [18, 20,
24] and etanercept (ETN; 1 trial) [23]. Ten trials were par-
allel design trials, while one trial [18] was a cross-over
design trial and combined both treatment periods.
Median trial duration was 24 weeks (range 1252 weeks).
A total of 1205 participants with clinically and radio-
graphically confirmed OA were included in the meta-ana-
lysis. Five trials examined participants with knee OA, of
which one [17] was restricted to participants with clinical
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signs indicative of synovitis. In contrast, the RCT by
Chevalier et al. [19] excluded participants with effusions
and inflammatory flares. The remaining six trials studied
participants with hand OA. Three of these trials [18, 23, 24]
were restricted to participants with erosive hand OA. In
addition, a further hand OA trial was limited to participants
with OA that was refractory to analgesics [20].
In the six studies that presented the gender distribu-
tions of participants, approximately three-quarters of the
participants were women (78.2%). The mean age of par-
ticipants in the eight trials where age data were available
ranged from 47.9 years [21] to 62.6 years [19].
Bias within and across trials
Potential risk of bias was demonstrated in the analysed
trials (Fig. 2). The primary sources of bias were selective
outcome reporting and incomplete outcome data, where
over half the studies were associated with high risks of
bias. Online trial registrations were found for six studies,
and a published protocol was found for one study. These
were compared with the outcomes available in the
included publication, and the publications most com-
monly did not include all pre-specified outcomes, did
not fully present the outcomes or conducted analyses
that had not been pre-specified. Furthermore, many
trials excluded participants from analysis [17, 18, 22,
23], used inappropriate methods for imputation of data
(e.g. last observation carried forward) [19, 24], or did not
provide sufficient detail regarding the amount of missing
data or how it was handled [20, 21, 25, 26, 27]. These
domains cause concerns about the risk of bias of the
included trials.
All trials were reported as double-blinded; however, the
adequacy of the blinding methods could not be deter-
mined in 5 of the 11 trials, due to insufficient information
in the publications. The remaining RCTs described appro-
priate procedures for blinding of participants, physicians
and outcome assessors.
Nearly half (45%) of the studies reported adequate
methods of allocation concealment, most commonly
through central allocation external to the study investiga-
tors. One trial [25] allocated treatment by the order of en-
rolment to the trial, and this was deemed to have a high
risk of bias. There was no evidence of funnel plot asym-
metry (P= 0.121) (supplementary Fig. S1, available at
Rheumatology online).
FIG. 1 PRISMA flow diagram
Results of the literature search.
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Efficacy of DMARDs in OA
Pain
Overall, the pooled result of outcomes for conventional
and biologic DMARDs was statistically superior to that
for outcomes for placebo with respect to pain relief
(Fig. 3 and Table 2). The ES was 0.18 (95% CI: 0.03,
0.34). The estimate was associated with a moderate
level of inconsistency (I2 = 41.7%) [8]; however, the test
for heterogeneity was not statistically significant
(P= 0.071). A sensitivity analysis including only high-qual-
ity trials, using adequate allocation concealment as a
quality indicator, showed no difference between
DMARDs and placebo (ES = 0.11, 95% CI: 0.06, 0.28)
(Table 2). No heterogeneity was evident in the estimate.
Furthermore, separate examination of conventional and
biologic DMARDs found that neither conventional (ES =
0.24, 95% CI: 0.05, 0.54) nor biologic (ES = 0.16, 95%
CI: 0.02, 0.34) DMARDs were superior to placebo for
pain relief. Large and significant heterogeneity was
observed across the conventional DMARD trials.
However, the results for biologic DMARDs were homoge-
neous, and this homogeneity was retained when
examined by mechanism of action. Neither IL1-inhibitors
(ES = 0.14, 95% CI: 0.16, 0.45) nor TNF-inhibitors
(ES = 0.17, 95% CI: 0.05, 0.54) were effective.
Further subgroup analyses found that the lack of effi-
cacy of treatment compared with placebo did not vary by
the joint site (hand vs knee OA), inflammatory phenotype
(erosive vs non-erosive hand OA) or publication type (con-
ference abstract or full text).
Inflammation and AEs
Only six studies assessed inflammation. One found a statis-
tically significant improvement (US synovitis) [16], one found
a clinically relevant improvement (clinical and US) [17], and
four found no difference between treatment and placebo
(MRI, serum and tissue CRP, effusion) [15, 18, 20, 24].
However, no quantitative data were available for further ana-
lysis. AE incidence was poorly reported across trials and
was not aggregated.
Discussion
This first meta-analysis of conventional and biologic
DMARDs in OA, including 11 RCTs with over 1200 partici-
pants, did not demonstrate statistically significant pain
relief from either conventional or biologic DMARDs com-
pared with placebo. Biologics, in particular, showed
homogeneity across studies. Conventional and biologic
DMARDs, when combined, were statistically superior to
placebo (ES = 0.18, 95% CI: 0.03, 0.34), but this was far
below the minimal clinically important difference threshold
(ES = 0.5) used in the UK [13]. Moreover, examination of
only high-quality trials with adequate allocation conceal-
ment did not produce statistically significant results
(ES = 0.11, 95% CI: 0.06, 0.28), and this estimate was
homogeneous. Any benefit observed is likely overesti-
mated by the risk of bias associated with selective out-
come reporting [8]. Furthermore, the analysis is based on
peak time point for the intervention, so even at their most
effective time-point these treatments do little better than
placebo.
Although the use of biologic DMARDs in OA has been
heralded as a promising way forward based on in vitro,
animal model and uncontrolled pilot studies, narrative re-
views have indicated that they do not appear to have any
clear benefit over placebo in RCTs [2830]. This is con-
firmed by the present meta-analysis, which is able to pro-
vide quantitative evidence for a lack of statistical
superiority of biological DMARDs over placebo. In con-
trast, the perceived efficacy of conventional DMARDs in
the literature is mixed. For example, the ACR specifically
advises against the use of MTX and does not offer any
recommendations on HCQ due to limited evidence [31],
whereas others favour a positive effect for MTX and HCQ
FIG. 2 Risk of bias of analysed trials
Cochrane’s Risk of Bias assessment [8] across all trials included in the meta-analysis. Percentage of trials scoring low
risk, unclear risk and high risk of bias across seven domains of bias.
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FIG. 3 Forest plot of DMARDs vs placebo in OA
Hedges’ effect size (ES) and 95% CI presented for pain at peak time point for intervention arm. ADA: adalimumab;
ANK: anakinra; ETN: etanercept.
TABLE 2 Overall, sensitivity and subgroup meta-analysis results for biologic and conventional DMARDS in OA
Analysis No. of trials No. analysed ES (95% CI) I2 (P-value)
Overall 11 1205 0.18 (0.03 to 0.34) 41.7% (0.071)
Sensitivity analysis
Allocation concealment 5 765 0.11 (0.06, 0.28) 0.0% (0.818)
Subgroup analysis
DMARD type
Biologic DMARD 5 448 0.16 (0.02, 0.34) 0.0% (0.975)
IL1-inhibitors 1 170 0.14 (0.16, 0.45) .
TNF-inhibitors 4 278 0.17 (0.05, 0.39) 0.0% (0.926)
Conventional DMARD 6 757 0.24 (0.05, 0.54) 70.0% (0.005)
Joint
Knee 5 477 0.34 (0.05 0.73) 71.7% (0.007)
Hand 6 728 0.09 (0.05, 0.24) 0.0% (0.948)
OA type
Erosive hand OA 3 193 0.19 (0.06, 0.45) 0.0% (0.846)
Non-erosive hand OA 3 535 0.05 (0.12, 0.22) 0.0% (0.979)
Publication type
Conference abstract 4 547 0.11 (0.05, 0.27) 0.0% (0.925)
Full text 7 658 0.27 (0.01, 0.55) 62.7% (0.013)
Presented as Hedges’ effect size (ES) and associated 95% CI. I2 (the variation in ES attributable to heterogeneity) and
associated P-values are presented.
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[30, 32]. However, the previously reviewed evidence is
limited to retrospective or non-blinded trials [32] and the
results of an RCT for MTX that has since been retracted
due to serious flaws and concerns about the reliability of
the data [33].
Targeting the innate immune response (through IL1),
adaptive immune response (through TNF) and the overall
level of inflammation (through MTX) without major effects
on pain suggests that inflammation may not be a key
driver of OA pain [2]. This view is further supported by
the lack of efficacy across the spectrum of inflammatory
phenotypes (from no effusion/inflammatory flares to syno-
vitis or erosive hand OA) and joint sites. The poor efficacy
of these drugs, which are used for RA [5], may indicate
that the quantity and/or role of inflammation in OA differs
from the primary aggressive inflammation in inflammatory
arthritides. Alternatively, the investigated drugs may not
be targeting the correct inflammatory pathways or may
not be using the drug at sufficient exposures to capture
a clinical effect. Better understanding of pain mechanisms
and the role of inflammation in OA is required in order to
identify and develop more effective treatments.
Limitations
The study is subject to several limitations. First, the meta-
analysis included conference abstracts that have not been
subject to the more stringent level of peer review as full
texts. Furthermore, abstracts do not allow full examination
of methods and critical appraisal of risks of bias. As a
result, the overall risk of bias of the included trials was
difficult to ascertain. However, the inclusion of abstracts
ensured that the evidence captured was as complete as
possible, which was partially reflected by the lack of
publication bias [34]. Second, data were not sought
from investigators and two trials were not included in
the meta-analysis as pain data were not available for ex-
traction from the conference abstracts. However, those
trials included a total of 90 participants and their exclusion
represents a loss of only 7% of the total participant popu-
lation. Third, it was not possible to examine inflammation
and AEs in a meta-analysis due to lack of information and
inconsistent reporting. Fourth, the overall results and con-
ventional DMARD-specific results were associated with
considerable and significant heterogeneity. The predom-
inant source of heterogeneity was the RCT by Jokar et al.
[19], which had a considerably younger [mean (S.D.) age
47.9 (9.8)] and predominantly (98%) female population
with overall low degrees of radiographic OA. This trial re-
ported an extraordinarily high ES for HCQ (1.38, 95% CI:
0.71, 2.04). Its exclusion from analysis increased homo-
geneity (to I2= 0.0%); however, the conclusions remained
unchanged. Fifth, subgroup analyses were based on rela-
tively small numbers of trials, which may limit the power of
this meta-analysis to detect significant differences within
the subgroups. Finally, the use of treatment peak time
point as the time point for analyses likely overinflates the
effect size estimate. However, it was chosen under the
assumption that if no difference was evident at the most
effective time-point, then the conventional and biologic
DMARDs were unlikely to be effective. It also allowed
more trials to be analysed. Displaying only a small effect
at their peak, conventional and biologic DMARDs are un-
likely to have considerable, or in fact any, effect at other
time points.
Conclusion
Neither conventional nor biological DMARDs relieve pain
due to OA. There is no difference between anti-IL1 and
anti-TNF biologics, and no difference between treating
erosive vs non-erosive hand OA or hand vs knee OA.
Although combining all DMARDs provided statistically sig-
nificant pain relief, this was not clinically significant, nor
was it supported by sensitivity analyses of high-quality
trials. The results suggest that inflammation may not be
a principal risk factor for OA pain.
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